226 related articles for article (PubMed ID: 16988542)
1. Regression of grade III astrocytoma during the treatment of CML with imatinib mesylate.
Jayawardena S; Sooriabalan D; Indulkar S; Kim HH; Matin A; Maini A
Am J Ther; 2006; 13(5):458-9. PubMed ID: 16988542
[TBL] [Abstract][Full Text] [Related]
2. Influence of imatinib mesylate on radiosensitivity of astrocytoma cells.
Ranza E; Bertolotti A; Facoetti A; Mariotti L; Pasi F; Ottolenghi A; Nano R
Anticancer Res; 2009 Nov; 29(11):4575-8. PubMed ID: 20032406
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
4. Primary anaplastic pilocytic astrocytoma.
Azad A; Deb S; Cher L
J Clin Neurosci; 2009 Dec; 16(12):1704-6. PubMed ID: 19815416
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
[TBL] [Abstract][Full Text] [Related]
6. Ukrain therapy in a frontal anaplastic grade III astrocytoma (case report).
Steinacker J; Kroiss T; Korsh OB; Melnyk A
Drugs Exp Clin Res; 1996; 22(3-5):275-7. PubMed ID: 8899347
[TBL] [Abstract][Full Text] [Related]
7. Low-grade astrocytomas of childhood.
Rekate HL; Rakfal SM
Neurol Clin; 1991 May; 9(2):423-40. PubMed ID: 1944108
[TBL] [Abstract][Full Text] [Related]
8. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
Kantarjian H; O'Brien S; Talpaz M; Borthakur G; Ravandi F; Faderl S; Verstovsek S; Rios MB; Shan J; Giles F; Cortes J
Cancer; 2007 Apr; 109(8):1556-60. PubMed ID: 17342766
[TBL] [Abstract][Full Text] [Related]
9. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
10. Gamma Knife surgery for low-grade astrocytomas: evaluation of long-term outcome based on a 10-year experience.
Wang LW; Shiau CY; Chung WY; Wu HM; Guo WY; Liu KD; Ho DM; Wong TT; Pan DH
J Neurosurg; 2006 Dec; 105 Suppl():127-32. PubMed ID: 18503345
[TBL] [Abstract][Full Text] [Related]
11. Multi-drug versus single agent chemotherapy for high grade astrocytoma; results of a meta-analysis.
Huncharek M; Muscat J; Geschwind JF
Anticancer Res; 1998; 18(6B):4693-7. PubMed ID: 9891542
[TBL] [Abstract][Full Text] [Related]
12. Tenascin-C expression relates to clinicopathological features in pilocytic and diffuse astrocytomas.
Maris C; Rorive S; Sandras F; D'Haene N; Sadeghi N; Bièche I; Vidaud M; Decaestecker C; Salmon I
Neuropathol Appl Neurobiol; 2008 Jun; 34(3):316-29. PubMed ID: 17983425
[TBL] [Abstract][Full Text] [Related]
13. Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.
Capper D; Mittelbronn M; Meyermann R; Schittenhelm J
Acta Neuropathol; 2008 Feb; 115(2):249-59. PubMed ID: 17965865
[TBL] [Abstract][Full Text] [Related]
14. Multicentric anaplastic astrocytoma in a child.
Khongkhatithum C; Visudtibhan A; Chiemchanya S; Visudhiphan P; Sanvivad P; Larbcharoensub N; Phudhicharoenrat S
J Clin Neurosci; 2007 Feb; 14(2):176-9. PubMed ID: 17161293
[TBL] [Abstract][Full Text] [Related]
15. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
Deininger MW; Cortes J; Paquette R; Park B; Hochhaus A; Baccarani M; Stone R; Fischer T; Kantarjian H; Niederwieser D; Gambacorti-Passerini C; So C; Gathmann I; Goldman JM; Smith D; Druker BJ; Guilhot F
Cancer; 2007 Oct; 110(7):1509-19. PubMed ID: 17702093
[TBL] [Abstract][Full Text] [Related]
16. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
[TBL] [Abstract][Full Text] [Related]
17. Hypolipemiant besides antileukemic effect of imatinib mesylate.
Gologan R; Constantinescu G; Georgescu D; Ostroveanu D; Vasilache D; Dobrea C; Iancu D; Popov V
Leuk Res; 2009 Sep; 33(9):1285-7. PubMed ID: 19327828
[TBL] [Abstract][Full Text] [Related]
18. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
[TBL] [Abstract][Full Text] [Related]
19. [Gliomas in adults: primary non-surgical treatment].
Poulsen HS
Ugeskr Laeger; 2006 Nov; 168(47):4082-5. PubMed ID: 17134603
[TBL] [Abstract][Full Text] [Related]
20. Detection of complete response to imatinib mesylate (Glivec/Gleevec) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma.
Kalender ME; Sevinc A; Yilmaz M; Ozsarac C; Camci C
Cancer Chemother Pharmacol; 2009 Feb; 63(3):555-9. PubMed ID: 18607592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
